Fezolinetant making waves for VMS

In this episode of Pap Talk, Contemporary OB/GYN® Associate Editor Lindsey Carr sat down with Jessica Shim, MD, an attending at in the Division of Gynecology, Department of Surgery, Boston Children’s Hospital; Harvard Medical School Boston, Massachusetts, to discuss Myfembree (relugolix, estradiol, and norethindrone acetate tablets; Myovant Sciences, Pfizer) and its possible approval in May 2022.

The New Drug Application (NDA) acceptance is supported by positive data from 3 clinical trials (OASIS 1, 2, and 3).

In this episode of Pap Talk, Contemporary OB/GYN® sat down with Maneesh Jain, CEO of Mirvie, and Michal Elovitz, MD, chief medical advisor at Mirvie, a new RNA platform that is able to predict pregnancy complications by revealing the biology of each pregnancy. They discussed recently published data regarding the platform's ability to predict preeclampsia and preterm birth.

Review some of the top stories from the Contemporary OB/GYN website over the last week, and catch up on anything you may have missed.

In a recent study, only 22.7% of women had menopause symptoms documented in their electronic health record, highlighting low rates of diagnosis and treatment.